HEALTHSTORY 653· JUNE 24, 2026

WHO-Backed Clinical Trial to Test Remdesivir and MBP-134 Against Bundibugyo Ebolavirus in DRC

A clinical trial set to begin next week in the Democratic Republic of the Congo will test Gilead Sciences' antiviral drug remdesivir and MappBio's monoclonal antibody MBP-134 against the Bundibugyo ebolavirus, the World Health Organization…

NDNewsDialy Desk2 MIN READ

SOURCE

statnews.com

← PREVIOUS STORY 652Asia Technology Stocks Mostly Rebound After Global Rout; Samsung Gains 9%NEXT STORY 654 →Federal Judge Blocks Texas Prosecutors From Subpoenaing Transgender Patient Records at New York Hospitals

Keep reading

More from the desk.

11HEALTH

Teresa Nunes joins EpilepsyGTx as chief medical officer

A chief medical officer (the executive who owns a company's clinical strategy and translates scientific findings into decisions the broader organization can act on) has taken a new position. Teresa Nunes, who held that title at Allucent…

health1 MIN

16HEALTH

Senate contempt vote against Anthony Fauci diverts attention from China's documented obstruction of Covid-19 data

A Senate committee voted last week to hold Anthony Fauci in contempt of Congress after he invoked the Fifth Amendment, the constitutional protection against self-incrimination, during hearin

health2 MIN

36HEALTH

FDA clears Replimune's melanoma drug Tudriqev after two rejections

A cancer treatment rejected twice by federal regulators has now won approval. The Food and Drug Administration granted accelerated approval to Tudriqev, a drug made by the biotech company Replimune, for patients with advanced melanoma…

health2 MIN

Tomorrow · 06:00

Start tomorrow already ahead.

Five stories, a two-minute read, zero noise — the world before your first coffee.

Get the 6AM brief Back to the desk